---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-116023"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:09:08.983076+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcellx Q1 net loss $62.3M; cash $565M; iMMagine-3 adds MRD endpoint

## Summary
- Net loss of $62.3M vs $7.2M in Q1 2024; collaboration revenue down to $8.1M from $39.3M.
- Cash and equivalents $565.2M; funding expected into 2028.
- iMMagine-1 data (117 patients) accepted for oral presentation at EHA June 14, 2025.
- iMMagine-3 study updated to include MRD negativity as dual primary endpoint alongside PFS.
- Appointed Andrew Galligan and Kristin Myers to Board; anito-cel launch planned for 2026.

## SEC filing metadata
- accession: 0001193125-25-116023
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312525116023/0001193125-25-116023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312525116023/d916048d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-116023
- JSON: https://secwatch.observer/filing/0001193125-25-116023.json
- Plain text: https://secwatch.observer/filing/0001193125-25-116023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.